
    
      The investigators hypothesis focuses on the effect of riboflavin given for the first three
      hours of ischemic stroke, as a reducing agent of cerebral glutamate concentration. This
      administration would produce a reduction of excitotoxic damage and consequently generate
      clinical improvement, while a lower income and a better functional outcome of patients at
      three months.
    
  